Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger Stupp

Showing results (261-270 of 314) with videos related to

Pageof 32
Sort By:
Neuro-Oncology|November 1, 2020
Memory in low-grade glioma patients treated with radiotherapy or temozolomide: a correlative analysis of EORTC study 22033-26033Martin Klein, A Josephine Drijver, Martin J van den Bent, et al.
Oncogene|June 13, 2020
Ribosomal protein S11 influences glioma response to TOP2 poisonsChidiebere U Awah, Li Chen, Mukesh Bansal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2010
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working groupPatrick Y Wen, David R Macdonald, David A Reardon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 9, 2013
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trialMark R Gilbert, Meihua Wang, Kenneth D Aldape, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2021
Glioblastoma Clinical Trials: Current Landscape and Opportunities for ImprovementStephen J Bagley, Shawn Kothari, Rifaquat Rahman, et al.
Acta Neuropathologica|January 31, 2020
cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomasDaniel J Brat, Kenneth Aldape, Howard Colman, et al.
Neuro-Oncology Advances|January 7, 2021
Calculating the net clinical benefit in neuro-oncology clinical trials using two methods: quality-adjusted survival effect sizes and joint modelingMarijke B Coomans, Linda Dirven, Neil K Aaronson, et al.
Acta Neuropathologica|January 18, 2012
Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trialMonika E Hegi, Robert-Charles Janzer, Wanyu L Lambiv, et al.
The Lancet. Oncology|May 4, 2023
Repeated blood-brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: a phase 1 trialAdam M Sonabend, Andrew Gould, Christina Amidei, et al.
Acta Neuropathologica|January 26, 2018
The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033Pierre Bady, Sebastian Kurscheid, Mauro Delorenzi, et al.
Pageof 32

Showing results (261-270 of 314) with videos related to

Sort By:
Pageof 32
Neuro-Oncology|November 1, 2020
Memory in low-grade glioma patients treated with radiotherapy or temozolomide: a correlative analysis of EORTC study 22033-26033Martin Klein, A Josephine Drijver, Martin J van den Bent, et al.
Oncogene|June 13, 2020
Ribosomal protein S11 influences glioma response to TOP2 poisonsChidiebere U Awah, Li Chen, Mukesh Bansal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2010
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working groupPatrick Y Wen, David R Macdonald, David A Reardon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 9, 2013
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trialMark R Gilbert, Meihua Wang, Kenneth D Aldape, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2021
Glioblastoma Clinical Trials: Current Landscape and Opportunities for ImprovementStephen J Bagley, Shawn Kothari, Rifaquat Rahman, et al.
Acta Neuropathologica|January 31, 2020
cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomasDaniel J Brat, Kenneth Aldape, Howard Colman, et al.
Neuro-Oncology Advances|January 7, 2021
Calculating the net clinical benefit in neuro-oncology clinical trials using two methods: quality-adjusted survival effect sizes and joint modelingMarijke B Coomans, Linda Dirven, Neil K Aaronson, et al.
Acta Neuropathologica|January 18, 2012
Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trialMonika E Hegi, Robert-Charles Janzer, Wanyu L Lambiv, et al.
The Lancet. Oncology|May 4, 2023
Repeated blood-brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: a phase 1 trialAdam M Sonabend, Andrew Gould, Christina Amidei, et al.
Acta Neuropathologica|January 26, 2018
The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033Pierre Bady, Sebastian Kurscheid, Mauro Delorenzi, et al.
Pageof 32